Published in PLoS Negl Trop Dis on November 29, 2012
Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int (2014) 0.95
Alginate Particles as Platform for Drug Delivery by the Oral Route: State-of-the-Art. ISRN Pharm (2014) 0.91
Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. Hum Vaccin Immunother (2013) 0.88
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell (2015) 0.78
Alternative activation of macrophages. Nat Rev Immunol (2003) 27.53
Human schistosomiasis. Lancet (2006) 10.87
Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop (2003) 6.64
Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity (2004) 6.46
Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature (2007) 5.82
The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology (1965) 5.24
Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 4.41
Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. J Exp Med (2006) 4.11
Current status of vaccines for schistosomiasis. Clin Microbiol Rev (2008) 3.47
Schistosomiasis. Nat Rev Microbiol (2004) 3.47
Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release (2001) 2.84
Immunopathology of schistosomiasis. Immunol Cell Biol (2006) 2.74
TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J Immunol (2008) 1.97
Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci U S A (2012) 1.74
Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine (2011) 1.58
Chitosan: some pharmaceutical and biological aspects--an update. J Pharm Pharmacol (2001) 1.56
Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis (2008) 1.54
Toward the elimination of schistosomiasis. N Engl J Med (2009) 1.54
Schistosomiasis: from risk assessment to control. Trends Parasitol (2002) 1.44
Schistosomiasis vaccine:research to development. Parasitol Today (1998) 1.38
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2006) 1.38
Cytokine regulation of granuloma formation in schistosomiasis. Curr Opin Immunol (1995) 1.36
Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine (2003) 1.29
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol (2008) 1.25
Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar Drugs (2010) 1.22
Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun (2004) 1.17
Chitosan-based nanoparticles for topical genetic immunization. J Control Release (2001) 1.11
Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitol Res (2002) 1.08
The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line(1). J Nutr Biochem (2002) 1.05
Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release (2006) 1.04
Novel approaches to vaccine delivery. Pharm Res (2004) 1.03
Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol (2005) 1.00
Th1 adjuvant N-acetyl-D-glucosamine polymer up-regulates Th1 immunity but down-regulates Th2 immunity against a mycobacterial protein (MPB-59) in interleukin-10-knockout and wild-type mice. Infect Immun (2001) 0.99
Ultrasonication of chitosan and chitosan nanoparticles. Int J Pharm (2003) 0.97
Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol (2008) 0.94
Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm (2005) 0.91
Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul (2010) 0.90
Blood protein adsorption onto chitosan. Biomaterials (2002) 0.89
Improving chitosan-mediated gene transfer by the introduction of intracellular buffering moieties into the chitosan backbone. Acta Biomater (2009) 0.88
The potential of chitosan for the oral administration of peptides. Expert Opin Drug Deliv (2005) 0.87
Why don't we have a schistosomiasis vaccine? Parasitol Today (1998) 0.87
Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates. J Virol (1997) 0.86
Identification of Ras, MAP kinases, and a GAP protein in Schistosoma mansoni by immunoblotting and their putative involvement in male-female interaction. Parasitology (1997) 0.85
Production and characterization of human monoclonal antibodies against Schistosoma mansoni. Parasite Immunol (1989) 0.85
Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. J Control Release (2010) 0.84
Oral vaccination based on DNA-chitosan nanoparticles against Schistosoma mansoni infection. ScientificWorldJournal (2012) 0.83
Characterisation of a Rho homologue of Schistosoma mansoni. Int J Parasitol (2003) 0.83
An influence of the structure of alginate on the chemotactic activity of macrophages and the antitumor activity. Carbohydr Res (1993) 0.83
Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur J Pharm Sci (2011) 0.82
Endotoxin contamination in wound dressings made of natural biomaterials. J Biomed Mater Res B Appl Biomater (2003) 0.81
Protective effect of rPb40 as an adjuvant for chemotherapy in experimental paracoccidioidomycosis. Mycopathologia (2012) 0.79
Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine (1999) 0.78
Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Pat (2010) 0.78
Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery. J Pharm Pharmacol (2006) 0.78
Development of an antipathology vaccine for schistosomiasis. Ann N Y Acad Sci (1996) 0.76
The type III inositol 1,4,5-trisphosphate receptor preferentially transmits apoptotic Ca2+ signals into mitochondria. J Biol Chem (2005) 2.00
The effect of ionic products from bioactive glass dissolution on osteoblast proliferation and collagen production. Biomaterials (2004) 1.45
Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant (2009) 1.14
Nuclear Ca2+ regulates cardiomyocyte function. Cell Calcium (2008) 1.09
Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med (2012) 1.00
Succinate modulates Ca(2+) transient and cardiomyocyte viability through PKA-dependent pathway. Cell Calcium (2009) 0.98
Molecular basis for pacemaker cells in epithelia. J Biol Chem (2002) 0.95
Endothelial differentiation of human stem cells seeded onto electrospun polyhydroxybutyrate/polyhydroxybutyrate-co-hydroxyvalerate fiber mesh. PLoS One (2012) 0.92
DAPI diffusion after intravitreal injection of mesenchymal stem cells in the injured retina of rats. Cell Transplant (2009) 0.91
Three-dimensional culture of rat BMMSCs in a porous chitosan-gelatin scaffold: A promising association for bone tissue engineering in oral reconstruction. Arch Oral Biol (2011) 0.87
Effect of a three-dimensional chitosan porous scaffold on the differentiation of mesenchymal stem cells into chondrocytes. Cells Tissues Organs (2009) 0.85
Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J Cell Mol Med (2013) 0.85
Osteogenic differentiation of mesenchymal stem cells using PAMAM dendrimers as gene delivery vectors. J Control Release (2008) 0.84
Protective effect and granuloma down-modulation promoted by RP44 antigen a fructose 1,6 bisphosphate aldolase of Schistosoma mansoni. Immunobiology (2007) 0.84
Oral vaccination based on DNA-chitosan nanoparticles against Schistosoma mansoni infection. ScientificWorldJournal (2012) 0.83
The combined use of Paracoccidioides brasiliensis Pb40 and Pb27 recombinant proteins enhances chemotherapy effects in experimental paracoccidioidomycosis. Microbes Infect (2011) 0.83
Additive effect of rPb27 immunization and chemotherapy in experimental paracoccidioidomycosis. PLoS One (2011) 0.82
Progress towards a needle-free hepatitis B vaccine. Pharm Res (2010) 0.81
Osteogenic differentiation of bone marrow mesenchymal stem cells of ovariectomized and non-ovariectomized female rats with thyroid dysfunction. Pathol Res Pract (2012) 0.80
In vitro and in vivo osteogenic potential of bioactive glass-PVA hybrid scaffolds colonized by mesenchymal stem cells. Biomed Mater (2012) 0.80
Hyaluronic acid/chitosan multilayer coatings on neuronal implants for localized delivery of siRNA nanoplexes. J Control Release (2013) 0.80
Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors. Oncol Rep (2013) 0.79
Modulation of granulomatous hypersensitivity against Schistosoma mansoni eggs in mice vaccinated with culture-derived macrophages loaded with PIII. Parasitol Int (2002) 0.79
Effect of nerve graft porosity on the refractory period of regenerating nerve fibers. J Neurosurg (2008) 0.78
GM-CSF and TNF-alpha synergize to increase in vitro granuloma size of PBMC from humans induced by Schistosoma mansoni recombinant 28-kDa GST. Immunol Lett (2004) 0.78
Immunization with rP22 induces protective immunity against Schistosoma mansoni: effects on granuloma down-modulation and cytokine production. Immunol Lett (2011) 0.78
A novel nanoparticle delivery system for in vivo targeting of the sciatic nerve: impact on regeneration. Nanomedicine (Lond) (2012) 0.76
Cytoplasmic-targeted parvalbumin blocks the proliferation of multipotent mesenchymal stromal cells in prophase. Stem Cell Res Ther (2013) 0.76
Mesenchymal stem cells associated with porous chitosan-gelatin scaffold: a potential strategy for alveolar bone regeneration. J Biomed Mater Res A (2012) 0.76
Human immune response in schistosomiasis: the role of P24 in the modulation of cellular reactivity to Schistosoma mansoni antigens. Hum Immunol (2002) 0.76
Chitosan-based nanoparticles as a hepatitis B antigen delivery system. Methods Enzymol (2012) 0.76
Identification of a new Schistosoma mansoni SMYB1 partner: putative roles in RNA metabolism. Parasitology (2013) 0.76
Validation of a new 96-well plate spectrophotometric method for the quantification of compound 48/80 associated with particles. AAPS PharmSciTech (2013) 0.75
Protein matrices for improved wound healing: elastase inhibition by a synthetic peptide model. Biomacromolecules (2010) 0.75
[Effect of triiodothyronine on the bone proteins expression during osteogenic differentiation of mesenchymal stem cells]. Arq Bras Endocrinol Metabol (2011) 0.75
The Present and the Future of Degradable Dendrimers and Derivatives in Theranostics. Bioconjug Chem (2015) 0.75
Fibroblast growth factor 9: cloning and immunolocalisation during tooth development in Didelphis albiventris. Arch Oral Biol (2005) 0.75
Chestnut cultivar diversification process in the Iberian Peninsula, Canary Islands, and Azores. Genome (2011) 0.75
Functionalized chitosan derivatives as nonviral vectors: physicochemical properties of acylated N,N,N-trimethyl chitosan/oligonucleotide nanopolyplexes. Soft Matter (2015) 0.75
Polymorphism analysis of the CTLA-4 gene in paracoccidioidomycosis patients. Mem Inst Oswaldo Cruz (2011) 0.75
Poly(hydroxybutyrate-co-hydroxyvalerate) bilayer skin tissue engineering constructs with improved epidermal rearrangement. Macromol Biosci (2014) 0.75